PI3K Alpha Selective Inhibitor Design via Local Quality
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PI3K inhibitors lack selectivity and efficacy in targeting PI3K alpha, particularly in treating proliferative diseases characterized by overexpression, amplification, or mutation of PIK3CA and PTEN, leading to inadequate therapeutic outcomes.
Innovation Solution
A 2-carboxamide cycloamino urea derivative is developed, exhibiting selective inhibition of PI3K alpha with improved metabolic stability, enhancing pharmacokinetic profiles and effectiveness in treating diseases mediated by PI3K alpha, such as tumors and leukemias.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current PI3K inhibitors are used, then PI3K inhibition is achieved, but selectivity for PI3K alpha is insufficient
Solution Approach 1:
The patent applies local quality by designing a inhibitor molecule with specific functional groups positioned to interact with unique features of the PI3K alpha active site. The compound contains a heteroaryl group, thiazole ring, and carboxamide moiety arranged in a specific configuration that creates localized interactions with PI3K alpha residues, enabling selective binding while maintaining inhibition of the target kinase.
Solution Approach 2:
The inhibitor exhibits asymmetry in its molecular structure with chiral centers that create non-superimposable mirror images. This asymmetric design allows the molecule to fit into the asymmetric binding pocket of PI3K alpha with high specificity, distinguishing it from other PI3K isoforms through stereoselective interactions that enhance alpha-selectivity.
2Reliability
If current PI3K inhibitors are used, then PI3K inhibition is achieved, but metabolic stability is insufficient
Solution Approach 1:
The patent applies parameter changes by modifying the chemical parameters of the inhibitor molecule, specifically incorporating metabolically stable heteroaryl and thiazole groups that resist enzymatic degradation. The molecular weight, lipophilicity, and hydrogen bonding capacity are optimized to achieve favorable pharmacokinetic properties including extended half-life and improved metabolic stability in vivo.
Data Source
AI summary
The present invention relates to a compound of formula (I) (I) or a salt thereof, wherein the substituents are as defined in the description, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-kinase.